Released Nov 9, 2011, after the close
10-Q filed Nov 9, 2011, 40 days after period end · 0001193125-11-304625
Q3 2011 · 10-Q
Revenue$26.38M$26.38M −0.3% vs Q3 2010−2.8% vs Q2 2011
Net Income$28.00K$28.00K −99.8% vs Q3 2010−98.0% vs Q2 2011
EPS Diluted$0.00$0.00 −100.0% vs Q3 2010−100.0% vs Q2 2011
Gross Profit$11,878,000−5.5%
Operating Income$220,000−88.7%
Operating Cash Flowderived$1,210,000−34.7%
Margins · derived
Gross margin45.0%−2.5 pt vs Q3 2010
Operating margin0.8%−6.5 pt vs Q3 2010
Net margin0.1%−48.0 pt vs Q3 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2011 | Q3 2010 |
|---|---|---|
| Revenue | $26.38M | $26.45M |
| Net Income | $28.00K | $12.73M |
| EPS Diluted | $0.00 | $0.44 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR